Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
IntroductionThere has been a growing concern regarding the interstitial lung disease (ILD) associated with HER2-targeted agents. This study aimed to elucidate the risk and characteristics of ILD associated with anti-HER2 agents using the FDA Adverse Event Reporting System (FAERS).MethodsData from 2004 Q1 to 2024 Q2 were extracted from the FAERS. The significant association between HER2-targeted agents and ILD was evaluated using the reporting odds ratio (ROR). Risk factors for mortality and time-to-onset were also assessed.ResultsA total of 2262 cases of HER2-targeted agents-associated ILD were identified. Positive signals were detected in trastuzumab deruxtecan (T-Dxd) (ROR = 31.28, 95% confidence interval [CI] 29.22-33.48), trastuzumab emtansine (T-DM1) (ROR = 6.27, 95% CI 5.38-7.32), pertuzumab (ROR = 6.08, 95% CI 5.36-6.89), trastuzumab (ROR = 4.02, 95% CI 3.73-4.33), tucatinib (ROR = 1.84, 95% CI 1.25-2.71), and lapatinib (ROR = 1.37, 95% CI 1.12-1.68). However, only two cases of ILD were associated with neratinib. The overall median time-to-onset was 75.5 days (interquartile range: 27.0-163.0). Logistic regression analysis revealed that elderly patients, treatment with T-Dxd, and treatment for non-breast cancer were significant risk factors for fatal outcomes related to ILD associated with HER2-targeted agents.ConclusionThis study suggests a significant association between the ILD and HER2-targeted agents, including T-Dxd, T-DM1, pertuzumab, trastuzumab, tucatinib, and lapatinib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10781552251356906 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2-Targeted Therapies and Cardiotoxicity: From Major Concern to Manageable Risk.
Curr Probl Cardiol
September 2025
Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA. Electronic address:
HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody-drug conjugates.
View Article and Find Full Text PDFWhat is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis.
J Cancer Res Ther
September 2025
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Background: The advent of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), has significantly improved survival in metastatic HER2-positive breast cancer (BC). Multiple anti-HER2 combination regimens are recommended as first-line treatments, but the optimal choice remains unclear. This study aimed to determine the optimal first-line regimen for metastatic HER2-positive BC through a network meta-analysis of clinical trial data.
View Article and Find Full Text PDFPersonalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics.
Expert Opin Biol Ther
September 2025
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Introduction: Metastatic colorectal cancer (mCRC) remains a leading cause of cancer mortality worldwide, with limited long-term survival despite therapeutic advances. The increasing understanding of its molecular heterogeneity has paved the way for precision medicine approaches aiming to optimize treatment efficacy and reduce unnecessary toxicity.
Areas Covered: This review provides an in-depth analysis of the current and emerging molecular targets in mCRC, including RAS, BRAF, HER2, and microsatellite instability.
Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer.
Zhejiang Da Xue Xue Bao Yi Xue Ban
August 2025
Comprehensive Genitourinary Cancer Center, the First Affiliated Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China.
Patients with metastatic castration-resistant prostate cancer (mCRPC) face poor prognoses due to tumor heterogeneity and drug resistance. Antibody-drug conjugates (ADCs) have been under development for over two decades for mCRPC treatment. Several clinical trials have demonstrated promising antitumor activity and acceptable safety profiles for ADCs in this setting.
View Article and Find Full Text PDFEvaluating Radiotheranostic Targets for Endometrial Cancer.
J Nucl Med
August 2025
Department of Chemistry, Hunter College, City University of New York, New York, New York;
Endometrial cancer is the most common gynecologic malignancy worldwide, and its incidence and mortality rates have increased over the past decade. Although early-stage disease is effectively treated via hysterectomy, a dearth of molecularly targeted therapies means that prognoses are far poorer for those with disseminated or recurrent disease. Herein, we describe the exploration of 3 biomarkers-human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24-as potential radiotheranostic targets for endometrial cancer.
View Article and Find Full Text PDF